Role of 4-1BB Ligand in Costimulation of T Lymphocyte Growth and its Upregulation on M12 B Lymphomas by cAMP by DeBenedette, M. A et al.
Dartmouth College
Dartmouth Digital Commons
Open Dartmouth: Faculty Open Access Articles
3-1-1995
Role of 4-1BB Ligand in Costimulation of T
Lymphocyte Growth and its Upregulation on M12
B Lymphomas by cAMP
M. A. DeBenedette
University of Toronto
N. R. Chu
University of Toronto
K. E. Pollok
Indiana University
J. Hurtado
Indiana University
William F. Wade
Dartmouth College
See next page for additional authors
Follow this and additional works at: https://digitalcommons.dartmouth.edu/facoa
Part of the Medical Sciences Commons
This Article is brought to you for free and open access by Dartmouth Digital Commons. It has been accepted for inclusion in Open Dartmouth: Faculty
Open Access Articles by an authorized administrator of Dartmouth Digital Commons. For more information, please contact
dartmouthdigitalcommons@groups.dartmouth.edu.
Recommended Citation
DeBenedette, M. A.; Chu, N. R.; Pollok, K. E.; Hurtado, J.; Wade, William F.; Kwon, Byoung S.; and Watts, Tania H., "Role of 4-1BB
Ligand in Costimulation of T Lymphocyte Growth and its Upregulation on M12 B Lymphomas by cAMP" (1995). Open Dartmouth:
Faculty Open Access Articles. 3175.
https://digitalcommons.dartmouth.edu/facoa/3175
Authors
M. A. DeBenedette, N. R. Chu, K. E. Pollok, J. Hurtado, William F. Wade, Byoung S. Kwon, and Tania H.
Watts
This article is available at Dartmouth Digital Commons: https://digitalcommons.dartmouth.edu/facoa/3175
Role of 4-1BB Ligand in Costimulation of T 
Lymphocyte Growth and its Upregulation on M12 B 
Lymphomas by cAMP 
By Mark A. DeBenedette,* N. Randall Chu,* Karen E. Pollok,~ 
Jos~ Hurtado,~ William F. Wade,$ Byoung S. Kwon,~ 
and Tania H. Watts* 
From the *Department of Immunology, University of Toronto, Toronto, Ontario, Canada M5S 
1A8; the *Department ofMicrobiology and Immunology, Indiana University, Indianapolis, 
Indiana 46202-5120; and the SDepartment ofMicrobiology and Immunology, Dartmouth 
Medical School, Lebanon, New Hampshire 03756 
Slltninlary 
K46J B lymphomas express aT cell costimulatory activity that is not inhibited by CTLA-4Ig, 
anti-B7-1, anti-B7-2, anti-intercellular dhesion molecule 1or antibodies to heat stable antigen. 
In this paper we report that this costimulatory activity is mediated at least in part by 4-1BB 
ligand, a member of the tumor necrosis factor (TNF) gene family that binds to 4-1BB, a T 
cell activation antigen with homology to the TNF/nerve growth factor eceptor family. A fusion 
protein between 4-1BB and alkaline phosphatase (4-1BB-AP) blocks T cell activation by K46J 
lymphomas in both an antigen-specific system and with polyclonally (anti-CD3) activated T 
cells. 4-1BB-AP also blocks antigen presentation bynormal spleen cells. When the antigen-presenting 
cells express B7 molecules as well as 4-1BB ligand, we find that B7 molecules and 4-1BB-AP 
both contribute to T cell activation. These data suggest that 4-1BB ligand plays an important 
role in costimulation of IL-2 production and proliferation by T cells. The B lymphoma M12 
expresses low levels of 4-1BB-L but can be induced to express higher levels by treatment of the 
B ceils with cAMP, which also induces B7-1 and B7-2 in these cells. Thus cAMP appears to 
coordinately induce several costimulatory molecules on B cells. 
T lymphocyte activation requires two signals. Signal I is 
provided when an antigen/MHC complex binds to the 
TCR and signal 2 is provided by TCR-independent interac- 
tions (1). The binding of costimulatory molecules B7-1 or 
B7-2 to CD28 on the T cell is now widely recognized as 
providing an important costimulatory signal for inducing high 
level IL-2 production and proliferation ofT cells (2, 3). How- 
ever, other molecules have been reported to have costimulatory 
roles in T cell activation. For example, the heat stable an- 
tigen has been reported to have costimulatory activity for T 
cell activation that synergizes with B7 (4-6). Intercellular and 
vascular cell adhesion molecules 1 (ICAM-1 and VCAM-1) 1, 
the ligands, respectively, for LFA-1 and very late antigen 4 
have also been shown to costimulate with anti-TCR in the 
costimulation of resting T cells (7). More recently, 4-1BB- 
ligand(L)-4-1BB interaction has been suggested toplay a role 
in the costimulation of lymphocyte growth (8, 9). 
4-1BB is a 55-kD protein expressed on activated CD4 and 
1 Abbreviations u ed in this paper: cAMP, cyclic AMP; 4-1BB-L, 4-1BB- 
ligand; ICAM-1, intercellular dhesion molecule 1.
CD8 T cells (8). It is a member of the nerve growth factor 
(NGF)/TNF receptor gene family, characterized bythe pres- 
ence of cysteine-rich motifs in the extracellular domains (for 
reviews see references 10 and 11). 4-1BB mtLNA is induced 
in T cells within hours of activation with anti-CD3 (12). 
However, surface xpression of 4-1BB is not detected until 
24-48 h after anti-CD3 treatment (8) and maximal expres- 
sion appears to require costimulation or cytokine treatment 
of the T cells and takes several days (12a). Initially, it was 
reported that 4-1BB binds to extracellular matrix proteins 
(13). However, more recently ahigh affinity ligand for 4-1BB 
has been identified on activated macrophages (9) and mature 
B cells (14). 4-1BB-L shows homology to TNF, LT-ol, LT-B, 
CD40L, and CD27L and thus appears to be a member of 
an emerging family of molecules that bind to members of 
the NGF/TNF receptor family (11). 4-1BB-L in CV-1 cells 
has been shown to costimulate with Con A in activation of 
thymocytes and with PHA in costimulation ofsplenic T cells 
(9). Moreover, antibody-mediated cross-linking of 4-1BB on 
anti-CD3-activated T cells profoundly enhances T cell prolifer- 
ation (8). 
In this report we have analyzed the ability of a 4-1BB- 
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alkaline phosphatase (AP) fusion protein to block T cell acti- 
vation in the presence and absence of B7 molecules. These 
data provide further evidence for the importance of 4-1BB- 
L-4-1BB interaction i  the costimulation of T lymphocyte 
activation. 
Materials and Methods 
Cell Lines, Antibodies and Reagents. The APC lines used in this 
study are described inTable I. The BALB/c lymphomas M12 and 
K46J were originally described by Kim et al. (15). An Ia-negative 
variant of M12, M12.C3, transfected with truncated A k (M12.C3. 
5C2,16) and the autoreactive Ak-restricted T hybrid C8.A3 (16) 
were obtained from Dr. Laurie Glimcher (Harvard Medical School, 
Boston, MA). K46J.73.35 (17), M12.C3.F6 (18), and M12.TDAK 
(19) transfectants have been described previously. Cells were main- 
tained in RPMI-1640 containing 10% FCS (P.A. Biologicals, Sydney, 
Australia), 50/~M 2-ME, MEM nonessential amino acids (GIBCO 
BILL, Gaithersburg, MD), antibiotics, pyruvate, and glutamine as 
previously described (20). 
20C9 antibody, specific for heat stable antigen (4) was provided 
as a culture supernatant byDr. Yang Liu (New York University 
Medical Center, New York). The B7-1 specific hybridoma 1610A1 
(21) was kindly provided by Dr. Hans Reiser (Dana Farber Cancer 
Institute, Boston, MA). The B7-2 specific hybridoma Gbl (22), 
the CD8-specific, rat IgG2a-secreting hybridoma 53.72.6, the A k- 
specific hybridoma 10-2.16, and the Ad-specific hybridoma MKD6 
were obtained from the American Type Culture Collection (Rock- 
ville, MD). The ICAM-l-specific hybridoma YN1 (23) was kindly 
provided by Fumeo Takei (University of British Columbia, Van- 
couver, Canada) and the anti-CD3-secreting hybridoma 145-2Cll 
(24) was kindly provided by Dr. Jeff Bluestone (University of 
Chicago, Chicago, IL). Antibodies were purified using protein 
G-Sepharose and labeled with biotin according to Goding (25). 
The mAb 1AH2 is a subdone of the antibody 53A2 specific for 
4-1BB described previously (8). The 4-1BB-AP fusion protein was 
prepared as previously described (14). The CTLA-4Ig fusion pro- 
tein (26) was provided in purified form by Peter Linsley (Bristol- 
Myers Squibb, Seattle, WA). Human placental AP was purchased 
from Sigma Chemical Co. (St. Louis, MO) and anti-AP was ob- 
tained from Medix Biotech Inc. (Foster City, CA). 
T Celllsolation. 6-8-wk-old BALB/c female mice were obtained 
from Charles River Laboratory (St-Constant, Quebec, Canada). 
Spleen cell suspensions were isolated from 8-10-wk-old mice, treated 
with 0.15 mM NH4C1 to lyse the RBC. MHC class II positive 
cells were depleted by treating the cell suspension with the A d- 
specific antibody MKD6 plus low-tox baby rabbit complement 
(Cedarlane, Hornby, Ont., Canada). T cells were further purified 
by passage over T cell enrichment columns from R&D Systems 
Inc. (Minneapolis, MN) and were ,v90% pure by anti-CD3 staining. 
Antigen Presentation Assays. Either 10 s C8.A3 T hybrids or 
5 x 104 normal splenic T cells were mixed with 105 or 2 • 105 
B lymphoma cells, respectively, and incubated overnight inthe pres- 
ence of various blocking antibodies. Supernatants were harvested 
and assayed for II:2 content using the CTLL indicator line as de- 
scribed (27). For both the I1:2 and the proliferation assays, data 
are expressed asmean _+ SD of triplicate cultures. 
Primary MLR cultures were prepared from mouse spleen using 
2 x 10 s BALB/c responder and 8 x 105 C3H stimulator cells. 
Responder T cells were nriched by passage through Sephadex G-10 
followed by Ab plus complement treatment ofthe eluted cells using 
anti-CD8 and anti-class II (MKD6) antibody. The stimulator popu- 
lation was depleted of T cells using anti-Thy 1.2 (HO13.4), anti- 
CD4 (RL172), and anti-CD8 mAb plus complement. Anti-Thyl 
and anti-CD4 were provided by Michael Julius (University of 
Toronto). The remaining viable cells were irradiated (2,000 fads). 
I1:2 content of the supernatants was measured onday 4 and prolifer- 
ation was measured on day 5, by harvesting cells that had been 
pulsed with [3H]thymidine for the previous 8 h of culture. 
Flow Cytometry. For flow cytometric analysis, cells were washed 
once in PBS and 106 cells in 200/ll of PBS, 1% FCS, 2 mM NaN3 
were incubated with irrelevant antibody to block Fc receptors be- 
fore the addition of biotinylated antibodies. After incubation, 
samples were washed and incubated with 200 #1 of a 1-/~g/ml 
solution of PE-streptavidin (BioMeda, Foster City, CA), followed 
by further washing. Samples were analyzed on a FACScan | (Becton 
Dickinson & Co., Mountain View, CA). Samples were monitored 
for forward versus side scatter and FL2 (for PE staining). Alignment 
was checked using Immunocheck beads and Autocomp software 
(Becton Dickinson & Co.). Propidium iodide staining and forward 
and side scatter were used to gate on live cells. Data were analyzed 
and plotted using Lysis II software (Becton Dickinson & Co.). In 
some xperiments, B lymphoma cells at a density of 5 x 10Vml 
were incubated overnight incomplete medium containing 300 r 
dibutyryl-cyclic (cAMP), as previously described (27). 
Results 
CTLA-4-independent Costimulation of T Cells by K46J B 
Lymphomas. Previous work from our laboratory at the 
University of Toronto and that of Laurie Glimcher has charac- 
terized the costimulatory equirements of a T cell hybrid, 
C8.A3. This T hybrid fails to respond to M12 B lymphomas 
expressing truncated A k molecules (16) unless they have been 
stimulated with cAMP (27) to induce B7-1 and -2 expres- 
sion (28-30) or unless they have been transfected with B7-1 
cDNA (28). Here we show that in contrast o the results 
with M12 B lyrnphomas (16), the BALB/c B lymphoma, K46J, 
when transfected with genes encoding truncated A k mole- 
cules, does not show the same antigen presentation defect 
(Table 1) and can stimulate C8.A3 T hybrids even in the pres- 
ence of CTLA-4Ig (Fig. 1). The CTLA-4Ig was used at a 
concentration f 20 #g/ml, which is more than sufficient 
to give maximal inhibition of antigen presentation by M12 
cells (29 and data not shown). These data suggest that K46J 
lymphomas express a costimulatory activity that does not 
involve CTLA-4 ligands. 
We also tested the ability of K46J cells to costimulate with 
immobilized anti-CD3 antibody to drive IL-2 production by 
normal T cells isolated from BALB/c spleens. We found that 
K46J lymphomas can costimulate normal T cells and that 
this activity does not appear to be sensitive to inhibition with 
antibodies against ICAM-1 nor to antibodies to heat stable 
antigen added either alone or in combination with CTLA4Ig 
(data not shown). Thus the ability of K46J cells to deliver 
costimulatory signals is independent ofB7 molecules, ICAM-1, 
and heat stable antigen. 
K46J B Lymphomas Express an Anti-B7-2 (GL-1) Binding 
Molecule that Does Not Appear to be Involved in Costimula- 
tion. Although the costimulatory activity of K46J B lym- 
phomas did not appear to be dependent on CTLA-4 ligands, 
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Tab le  1. Effect of MHC II Truncation on Antigen-presenting Ability of M12 and K46J Lymphomas 
A k A k IL-2 produced by C8.A3 s 
molecule specific 
APC expressed* fluorescence* - cAMP + cAMP 
M12.C3.F6 wt/wt 203 320 nt 
M12.C3.5C2 - 10 / -  12 43 <10 320 
M12.TDAK - 10 / -  12 181 <10 320 
K46J none 0 <10 <10 
K46J.73.35 - 12 / -  12 57 160 160 
* - 10/- 12 or - 12/- 12 indicates Ak molecules altered by site-directed mutagenesis to encode proteins lacking 10 or 12 amino acids from the 
COOH terminus of the B chain and 12 amino acids from the COOH terminus of the o~ chain. M12.TDAK and K46J express wild-type A d and 
E a molecules as well as the transfected A k molecules, whereas M12.C3.F6 and M12.C3.5C2 were obtained by transfecting the Ia negative cell line 
M12.C3 and express only wild-type or truncated Ak. 
* A k surface xpression was measured using FITC-10-2.16 antibody. Specific fluorescence r fers to the signal obtained with FITC-10-2.16 minus 
that obtained with a negative control antibody. 
S C8.A3 are autoreactive, Ak-restricted T cell hybrids. IL-2 activity is expressed asthe dilution of culture supernatant that gives 50% maximum 
thymidine incorporation by CTLL cells. 
we analyzed the surface xpression of these molecules on K46J 
B lymphomas. Surprisingly, we found that although K46J 
cells fail to bind CTLA-4Ig or anti-B7-1, they do stain with 
the B7-2-reactive antibody GL-1 but not with a control rat 
IgG2a antibody (data not shown). Despite the presence of 
a GL-1 (anti-B7-2) binding molecule on K46J ceils, B7-2 does 
not appear to be responsible for the costimulatory activity 
of K46J B lymphomas in that GL-1 antibody does not in- 
hibit antigen presentation by K46J B lymphomas (data not 
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Figure 1. Antigen presentation byK46J B lymphomas is not blocked 
by CTLA-41g. 105 autoreactive, Ak-restricted C8.A3 T hybrids were cul- 
tured for 18 h with 105 K46J.73.75 or 105 M12.TDAK cells. Cell lines 
are described inTable 1. Untreated M12.TDAK are included as a negative 
control here, since they do not stimulate C8.A3 cells unless treated with 
cAMP to induce B7 molecules. Supernatants were harvested and assayed 
for the presence ofIL-2 using CTLL cells. CTLA41g was added at a final 
concentration f 20 #g/ml. 
shown). Thus K46J cells express amolecule which binds B7- 
2-specific antibodies but does not appear to be involved in 
costimulation of T cells. Work is in progress to determine 
whether this molecule represents a mutated or posttransla- 
tionally modified form of B7-2 that lacks the CTLA-4 and 
CD28 binding site or whether it represents an unrelated mol- 
ecule that expresses the GL-1 epitope. 
Expression of 4-1BB-L on B Lymphomas. As discussed above, 
4-1BB, a member of the TNF/NGF receptor family, is an 
activation antigen on T cells that has been implicated in 
costimulation o fT  lymphocyte growth. Its ligand, 4-1BB-L, 
shows sequence homology to TNF and is found on activated 
macrophages, B cells, and B lymphomas. We examined K46J 
B lymphomas for the expression of 4-1BB-L using a soluble 
form of 4-1BB (14). Fig. 2 A shows that a fusion protein 
consisting of the extracellular domain of 4-1BB linked to AP 
(4-1BB-AP) stains K46J B lymphomas, whereas the AP itself 
does not. We therefore xamined the T cell hybrid C8.A3 
for expression of 4-1BB using mAb 1AH2. Resting C8.A3 
cells did not express detectable 4-1BB (data not shown), how- 
ever after overnight incubation with immobilized anti-CD3, 
4-1BB surface expression was readily detected (Fig. 2 B). 
It was of interest o determine whether 4-1BB ligand was 
also expressed on a B lymphoma that expressed B7 mole- 
cules. Fig. 2 A shows that M12 B lymphomas express low 
levels of 4-1BB-L constitutively but are induced to express 
much higher levels of 4-1BB-L upon overnight incubation 
in dibutyryl-cAMP, cAMP did not have an effect on 4-1BB-L 
expression on K46J cells, which already express high levels 
of the ligand (data not shown). 
4-1BB-L Is Critically Involved in Costimulation by K46J B Lym- 
phomas. Since activated C8.A3 cells express 4-1BB and K46J 
cells express its ligand, we tested the ability of the 4-1BB-AP 
fusion protein to inhibit IL-2 production by C8.A3 in re- 
sponse to K46J.73.75 cells. Fig. 3 A shows that the 4-1BB- 
AP fusion protein blocks IL-2 production by C8.A3 cells re- 
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Figure 2. Expression of the 4-1BB-L and 4-1BB counter-receptors n (A) B cells and (B) T cells, respectively. (.4) K46J B lymphoma cells were 
stained with either AP (open histograms) or 41BB-AP (filled histograms) followed by biotinylated anti-AP antibody. PE-streptavidin was used as the third 
step in the detection protocol. M12TDAK cells were untreated or treated with dibutyryl-cAMP as indicated on the figure and stained with 4-1BB-AP 
(untreated, cAMP) or AP alone (unlabeled histogram). (B) Filled histograms represent C8.A3 cells incubated overnight on plates coated with 10/~g/ml 
anti-CD3 antibody before flow cytometry analysis for 4-1BB expression, using biotinylated 1AH2 antibody. Open histograms represent staining of 
C8.A3 T cells with control biotinylated antibody. PE-streptavidin was used as the second step to detect biotinylated antibodies. 
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Figure 3. 4-1BB-AP blocks Ib2 production by C8.A3 T hybrids and 
by normal murine T cells. (A) C8.A3 T hybrids were incubated with A k 
transfected K46J B lymphomas (K46J. 73.35) and IL-2 production was as- 
sayed at 18 h using CTLL cells. (B) Normal murine T cells were co-cultured 
sponding to Ak-transfected K46J B lymphomas to near 
background levels whereas CTLA-4Ig has little or no effect. 
Fig. 3 B shows that IL-2 production by normal T cells to 
K46J plus anti-CD3 is also profoundly blocked by 4-1BB- 
AP fusion protein. In this and other experiments with normal 
T cells we observed some inhibition with CTLA4Ig also. 
Inasmuch as K46J does not express CTLA-4 ligands, this is 
likely due to failure to remove all the APC during T cell iso- 
lation. 
Although AP itself did not block T cell activation by K46J 
cells, it is formally possible that the 4-1BB fusion protein 
was somehow inhibitory to the T cells by some means other 
than by blocking the interaction of 4-1BB with its ligand. 
To test this possibility, we looked at the response of C8.A3 
T hybrids to immobilized anti-CD3. Although C8.A3 T 
hybrids require costimulation when responding to Ag/MHC 
II, they do respond to anti-CD3 alone, as in the case for most 
T cell hybrids. Fig. 4 shows that 4-1BB-AP does not affect 
IL-2 production by C8.A3 T cells responding to anti-CD3 
immobilized on plastic. 
To examine whether 4-1BB plays a role in T cell activa- 
tion in the presence of B7 molecules, we tested the effect of 
4-1BB-AP on T cell activation by M12 B lymphomas treated 
with cAMP. After overnight reatment with cAMP, M12 B 
lymphomas express limited amounts of B7-1 and high levels 
of B7-2 (data not shown). Fig. 5 shows that 4-IBB-AP pro- 
foundly blocks the activation of C8.A3 T cells by Ak-ex -
pressing M12 cells. Anti-B7-1 shows little or no effect in this 
experiment, presumably because high level B7-1 expression 
requires longer than the overnight APC activation carried 
with K46J B cells and immobilized anti-CD3 and assayed for Ib2 produc- 
tion as described in Fig. 2. The 4-1BB-AP fusion protein and the AP were 
added at a final concentration of 10 #g/ml. CTLA4Ig was added at a final 
concentration of 20 ~g/ml. 
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Figure 4.  Soluble 4-1BB does not inhibit anti-CD3 activated C8.A3 
T hybrids. 10 s C8.A3 T cells were incubated overnight on plates coated 
with 10 ~tg/ml anti-CD3. Ib2 production was assayed using CTLL cells. 
The 41BB-AP fusion protein and the AP were added at the beginning 
of the incubation at a final concentration f 10 #g/ml. 
out here (28). Anti-B7-2 gave inhibition comparable tothat 
observed with 4-1BB-AP alone. In combination, anti-B7-1, 
anti-B7-2, and 4-1BB-AP completely inhibited IL-2 produc- 
tion by C8.A3 in response to cAMP-treated M12 cells. Thus 
B7 molecules and 4-1BB-L each contribute independently o 
T cell activation when expressed on the same APC. 
Role of 4-1BB in Antigen Presentation by Splenic APC. 
4-1BB-L has been identified on activated macrophages as well 
as on B cells. To determine whether 4-1BB-L plays a role 
in T cell activation by splenic APC as well as by K46J B 
lymphomas we tested the ability of 4-1BB-AP to block T 
cell responses in a BALB/c anti-C3H MLR. Fig. 6 shows 
that both 4-1BB-AP and CTLA-4Ig added individually pro- 
foundly block proliferation and IL-2 production by the al- 
loreactive T cells. The combination of the two completely 
abrogated the response. These data suggest that both 4-1BB-L 
and B7 molecules play a role in costimulation by splenic APC. 
Discussion 
In this report we have shown that a fusion protein between 
4-1BB and AP profoundly blocks T cell activation both by 
B lymphomas and by unfractionated spleen cells. The effect 
of the 4-1BB-AP fusion protein appears to be on APC-T cell 
interaction, since 4-1BB-AP does not block T cell activation 
by immobilized anti-CD3. These data suggest that the fu- 
sion protein is blocking antigen presentation by blocking 
the interaction between 4-1BB and its ligand on the APC. 
4-1BB-L, a member of the TNF gene family, recently has 
been identified as a high affinity ligand for 4-1BB on acti- 
vated B cells and macrophages (9). However, the present ex- 
periments do not rule out that alternate low affinity ligands 
for 4-1.BB, namely extraceUular matrix components, also play 
a role (13). 
We find that 4-1BB plays a role in costimulation fT cell 
activation both in the presence of B7 molecules and in their 
apparent absence. M12 ceils, when treated overnight with 
dibutyryl-cAMP, express both B7-2 and 4-1BB-L as well as 
low levels of B7-1. Under these conditions of antigen pre- 
sentation we find that CTLA-4Ig and 4-1BB-AP each inhibit 
substantially. In contrast to the effects of CTLA4Ig alone 
(29) the combination of anti-B7-1, anti-B7-2, and 4-1BB- 
AP completely blocks antigen presentation by cAMP-treated 
M12 cells, suggesting that these molecules account for the 
majority of the costimulatory ligands on cAMP-treated M12 
cells. When spleen cells are used as stimulators in an MLR, 
we find that CTLA-4Ig and 4-1BB-AP each inhibit almost 
completely on their own. This suggests hat high level IL-2 
production may require multiple costimulatory signals, per- 
haps acting sequentially. Removal of either one of these signals 
is sufficient to abrogate the major part of the response. 
On K46J B lymphomas which lack functional B7 mole- 
cules, 4-1BB-L appears to be capable of costimulating C8.A3 
T cells in the absence of B7 molecules. Thus 4-1BB-4-1BB 
ligand interaction i  the absence of B7, can costimulate IL-2 
production. However, we do not know whether other mol- 
ecules on K46J are required or whether 4-1BB-L alone is 
sufficient for costimulation. This question will require anal- 
ysis of the function of 4-1BB-L in the absence of other APC 
molecules. Goodwin et al. (9) showed costimulation fsplenic 
T cells with PHA plus 4-1BB-L transfected CV-1 cells. How- 
ever, the fact that they used a lectin in these studies may have 
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Figure 5. 4-1BB-AP and anti-B7 antibodies have additive 
effects on the ability of M12 B cells to costimulate T cells. 
C8.A3 T cells were incubated with M12.TDAK B lymphomas 
and IL-2 production was assayed using CTLL cells as described 
in Materials and Methods. Anti-B7-1 (1610A1) and anti-B7-2 
(GL-1) antibodies were added to cultures at a final concentra- 
tion of 20/xg/ml. The 4-1BB-AP fusion protein and the AP 
were added at a final concentration f 10/~g/ml. 
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Figure 6. 4-1BB-AP blocks proliferation and Ib2 produc- 
tion in a 5-d BALB/c anti-C3H MLR.. (.4) Proliferation of 
T cells, measured at 5 d. (B) IL-2 content of the supernatant 
at 4 d was measured using CTLL cells. CTLA-41g and 
4-1BB-AP were each added at 10/~g/ml. Control refers to 
the addition of 10/~g/ml human IgG1. In other experiments, 
AP was used as a control with a similar lack of effect. 
resulted in cross-linking of several T cell surface proteins. On 
the other hand, Pollok et al. (8) have shown that the 53A2 
mAb, specific for 4-1BB, can costimulate with anti-CD3 to 
activate splenic T cells, again suggesting that 4-1BB-4-1BB-L 
interaction can function independently of B7 molecules to 
costimulate lymphocyte growth. 
The C8.A3 T hybrids used here, although costimulatory 
molecule dependent when stimulated using Ag/MHC, are 
costimulatory molecule independent when stimulated with 
anti-CD3. Therefore, it was of interest o determine whether 
4-1BB-L-4-1BB interaction plays a role in normal T ceil acti- 
vation. We found that K46J B lymphomas can costimulate 
with anti-CD3 to activate normal splenic T cells to produce 
IL-2 and induce T cell proliferation. This costimulatory ac- 
tivity of K46J was blocked by 4-1BB-AP, suggesting the im- 
portance of 4-1BB-4-1BB-L interaction in normal T cell ac- 
tivation. It is di~cult however to conclude from these data 
that 4-1BB-L alone is costimulatory because we often ob- 
served a small amount of inhibition with CTLA-4Ig in these 
experiments. This inhibition with CTLA-4Ig is presumably 
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due to residual APC in the T cell preparations, ince K46J 
cells do not stain with CTLA-4Ig. 
It is perhaps urprising that 4-1BB-AP blocks T cell acti- 
vation by M12 B lymphomas which also express B7 mole- 
cules, because B7-transfected CHO cells have been shown 
to be suffident o provide costimulation for T cells (30-33). 
In those studies the levels of B7 used were higher than those 
found on activated B cells and furthermore, the T cells were 
stimulated with anti-CD3. It is likely that under normal con- 
ditions when the physiological ligand for TCR (Ag/MHC) 
is used that several costimulatory molecules will contribute 
to T cell activation. 
On C8.A3 T cells, 4-1BB is detectable on the cell surface 
after overnight incubation with anti-CD3 (Fig. 2 B), consis- 
tent with our observation that 4-1BB-4-1BB-L plays a role 
in antigen presentation within the first 24 h of activation 
of C8.A3 T cells. However, for normal splenic T cells max- 
imal surface xpression of 4-1BB requires costimulation or 
exposure to cytokines and takes everal days (12a). Therefore, 
one must ask how 4-1BB-AP can block T cell activation be- 
fore the surface xpression of 4-1BB is detectable. Previous 
work (12) has established that 4-1BB mRNA is detectable 
within a few hours of stimulation with anti-CD3. It is pos- 
sible that low levels of 4-1BB are present on the cell surface 
within hours of contact of the T cells with APC and that 
these levels are sufficient o initiate T cell activation. These 
initial signals would then result in further amplification of 
4-1BB expression on the T cell. Alternatively, other mole- 
cules on K46J cells may contribute to the costimulatory signals 
which then allow induction of more 4-1BB on the T cell 
and further amplification of the costimulatory signals. 
Cross-linking of a number of surface receptors on T cells 
has been shown to augment T cell activation. However, many 
of these interactions function to enhance signals induced via 
the TCR, i.e., "signal 1". What distinguishes the CD28-B7 
interaction is that CD28 engagement results in the induc- 
tion of a distinct signal transduction pathway, hence the widely 
accepted view that CD28 is a major recipient of "signal 2" 
(2, 3). 4-1BB has been shown to associate with p56 lck (34), 
but at this time little else is known about its signal trans- 
ducing properties. It remains to be seen whether signals 
emanating from 4-1BB intersect hose signal transducing 
pathways activated by TCR, and/or CD28. 
4-1BB-L and 4-1BB are members of an emerging family 
of cytokine-like, cytokine receptor-like molecules, including 
TNF, TNFR; CD40L, CD40; and CD70, CD27 (9, 35). 
It is of interest, that CD27 on T cells interacting with CD70 
on human B cells shares many of the features of the 4-1BB- 
4-1BB-L system (36, 37). CD27 is present at low levels on 
mature T cells and upregulated by TCR signaling. Its ligand, 
CD70 is absent on resting B cells but upregulated by CD40 
signaling. CD70 has also been shown to be costimulatory 
for T cells and to have additive ffects with B7, however CD70 
has more of an effect on TNF-c~ production than on IL-2 
and IL-4 production by human T cells (36). It is tempting 
to speculate that various combinations of B7, 4-1BB-L, 
CD27L, and perhaps other costimulatory molecules, might 
influence the phenotype of T cell response one obtains. 
We have shown that in M12 cells, both B7 molecules and 
4-1BB-L are upregnlated by cAMP treatment. Thus several 
costimulatory molecules on APC can be induced by activa- 
tion. During antigen presentation, it is likely that both 4-1BB 
and 4-1BB-L are upregulated reciprocally allowing an 
amplification of the initial signals in much the same way as 
B7 and CD28 molecules and CD27 and CD70 are upregu- 
lated during T cell activation. This back and forth interac- 
tion between the two cells might serve to reinforce initial 
signaling events that take place upon the engagement ofjust 
a few TCR and a few costimulatory eceptors by their ligands, 
rendering the T cell exquisitely sensitive to antigenic hallenge. 
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